CN Menu
Press Release
Evergreen Therapeutics was successfully shortlisted for 2021 Top 100 Chinese Pharmaceutical Innovative Seed Enterprises
Source:Evergreen Date: Dec,2021 Views: 449

On December 21, 2021 China Pharmaceutical Entrepreneurs, Scientists and Investors Conference  was jointly sponsored by the China Pharmaceutical Enterprise Management Association, China Pharmaceutical Biotechnology Association, and Hangzhou Investment Promotion Bureau, officially held online.


The list of "2021 Top 100 Chinese Pharmaceutical Innovative Seed Enterprises" (CPISE 100) was released for the first time at this conference. The top 100 list is a continuation of the basic research framework of "Innovation 100", focusing on innovative foundation, innovative process, and innovative results. The evaluation system, based on Clarivate Analytics' Derwent patent data and Cortellis competitive intelligence and clinical trial data, selects more than 5,000 domestic start-ups that have unique innovative products or technologies and have not yet landed in the capital market. As a company founded only two years ago, Evergreen Therapeutics stood out in this selection with its efficient R&D strategy and fruitful innovative results, and was successfully shortlisted.

2010 CPISE 100 Certificate won by Evergreen

The company was founded in 2019 by a number of former FDA senior reviewers and technical experts and management talents with working experience in multinational pharmaceutical companies. The company is a Maryland-based innovative biotech company, and has office and laboratories the United States and China. Now it has multiple complete technology research and development platforms, focusing on the research and development of immune-related drugs (including oncoimmunology) and ophthalmic drugs. Phase I, Phase II and Phase III clinical trials are currently underway in the United States, South America and India.